PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer Research

• Publication date

  2008-03-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-07-5659PMID 18339877PMCID PMC3972216
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

  2007cited by this paper
• Immunohistochemical variability of epidermal growth factor receptor (EGFR) in liver metastases from colonic carcinomas

  2007cited by this paper
• Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis

  2007cited by this paper
• PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

  2007cited by this paper
• STAT‐mediated EGFR signaling in cancer

  2007cited by this paper
• Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

  2007cited by this paper
• Epidermal Growth Factor Receptor (EGFR) Expression is Associated With a Worse Prognosis in Gastric Cancer Patients Undergoing Curative Surgery

  2007cited by this paper
• Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

  2007cited by this paper
• Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

  2007cited by this paper
• A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

  2007cited by this paper
• KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

  2006cited by this paper
• Tissue Microarray Analysis of EGFR Gene Amplification and Gain in Bulgarian Patients with Colorectal Cancer

  2006cited by this paper
• Recurrent KRAS codon 146 mutations in human colorectal cancer

  2006influential reference
• Chemotherapy for Colorectal Cancer

  2006cited by this paper
• Mutation of the PI3′ Kinase Gene in a Human Colon Carcinoma Cell Line, HCC2998

  2006cited by this paper
• Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

  2005influential reference
• Autocrine growth stimulation of SW403 colon carcinoma cell line is caused by transforming-growth-factor-α-mediated epidermal growth factor receptor activation

  2005cited by this paper
• Colorectal cancer: Mutations in a signalling pathway

  2005influential reference
• Molecular determinants of cetuximab efficacy.

  2005cited by this paper
• Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer.

  2005cited by this paper
• Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.

  2005cited by this paper
• Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft

  2005cited by this paper
• Mutant PIK3CA promotes cell growth and invasion of human cancer cells.

  2005influential reference
• The prevalence of PIK3CA mutations in gastric and colon cancer.

  2005cited by this paper
• Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study

  2005cited by this paper
• Critical evaluation of current treatments in metastatic colorectal cancer.

  2005cited by this paper
• Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

  2005cited by this paper
• Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

  2004cited by this paper
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers

  2004cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004influential reference
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Somatic mutations of EGFR in colorectal cancers and glioblastomas.

  2004cited by this paper
• Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Epidermal growth factor receptor: mechanisms of activation and signalling.

  2003cited by this paper
• Color multiplex polymerase chain reaction for quantitative analysis of epidermal growth factor receptor genes in colorectal adenocarcinoma

  2003cited by this paper
• Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin.

  2003influential reference
• Epidermal growth factor receptor: mechanisms of activation and signalling.

  2003cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases.

  2002cited by this paper
• PTEN gene mutations in colorectal cancers displaying microsatellite instability.

  2001cited by this paper
• The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.

  2001cited by this paper
• Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis.

  2000cited by this paper
• Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c- jun N-terminal kinase activity

  2000cited by this paper
• Multiple Autocrine Factors Including an Extracellular Matrix Protein are Required for the Proliferation and Spreading of Human Colon Carcinoma Cells In Vitro

  2000cited by this paper
• Divergent phenotypic patterns and commitment to apoptosis of Caco‐2 cells during spontaneous and butyrate‐induced differentiation

  2000cited by this paper
• The EGF receptor family as targets for cancer therapy

  2000influential reference
• Chemotherapy for colorectal cancer.

  1994cited by this paper
• Altered growth of human colon cancer cell lines disrupted at activated Ki-ras.

  1993cited by this paper
• Autonomous proliferation of colon cancer cells that coexpress transforming growth factor alpha and its receptor. Variable effects of receptor-blocking antibody.

  1992cited by this paper
• Autonomous proliferation of colon cancer cells that coexpress transforming growth factor α and its receptor

  1992cited by this paper
• Chemotherapy of colorectal cancer.

  1991cited by this paper
• Detection of high incidence of K-ras oncogenes during human colon tumorigenesis

  1987cited by this paper

• Advances in Polymer Micelles for Cancer Therapy: From Conventional to Smart Delivery Systems.

  2026cites this paper
• Comprehensive review of the resistance mechanisms of colorectal cancer classified by therapy type

  2025cites this paper
• Analysis of PIK3CA mutation prevalence variation among colorectal cancer populations: a comprehensive review

  2025cites this paper
• Molecular Targets in Metastatic Colorectal Cancer: A Review

  2025cites this paper
• Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance

  2025cites this paper
• Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers.

  2025cites this paper
• Distinct Driver Pathway Enrichments and a High Prevalence of TSC2 Mutations in Right Colon Cancer in Chile: A Preliminary Comparative Analysis

  2024cites this paper
• Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies

  2024cites this paper
• Discovery, identification and mechanism of chemosensitivity-relate biomarker inter-α-trypsin inhibitor heavy chain 4 in metastatic colorectal cancer

  2024cites this paper
• A panorama of colon cancer in the era of liquid biopsy

  2024cites this paper
• Construction and significance of a breast cancer prognostic model based on cuproptosis-related genotyping and lncRNAs.

  2024cites this paper
• CDK4/6 inhibition to resensitize BRAF/EGFR inhibitor in patient-derived BRAF/PTEN-mutant colon cancer cells

  2023cites this paper
• PI3Kα Translocation Mediates Nuclear PtdIns(3,4,5)P3 Effector Signaling in Colorectal Cancer

  2023cites this paper
• SLC25A21 downregulation promotes KRAS-mutant colorectal cancer progression by increasing glutamine anaplerosis

  2023cites this paper
• Implication of thyroid hormone receptors in methamphetamine neurocognitive effects.

  2022cites this paper
• Drug Resistance in Colorectal Cancer: From Mechanism to Clinic

  2022cites this paper
• Characterization of Genomic Alterations in Colorectal Liver Metastasis and Their Prognostic Value

  2022cites this paper
• Liquid Biopsy and Artificial Intelligence as Tools to Detect Signatures of Colorectal Malignancies: A Modern Approach in Patient’s Stratification

  2022cites this paper
• Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers

  2022cites this paper
• Clinicopathological Significance of PTEN Expression and Its Prognostic Effect in Colorectal Adenocarcinoma Patients

  2022cites this paper
• Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death

  2022cites this paper
• Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer

  2022cites this paper
• Neuroprotective effect of thyroid hormones on methamphetamine-induced neurotoxicity via cell surface receptors.

  2022cites this paper
• Targeting feedback activation of signaling transduction pathways to overcome drug resistance in cancer.

  2022cites this paper
• Genetic alterations shaping tumor response to anti-EGFR therapies.

  2022cites this paper
• Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited

  2022influential citation
• Dual MAPK and HDAC inhibition rewires the apoptotic rheostat to trigger colorectal cancer cell death

  2021cites this paper
• Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR‐targeting agents to treat head and neck squamous cell carcinoma

  2021cites this paper
• CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS?

  2021cites this paper
• SOD2 Enhancement by Long-Term Inhibition of the PI3K Pathway Confers Multi-Drug Resistance and Enhanced Tumor-Initiating Features in Head and Neck Cancer

  2021cites this paper
• Liver Endothelium Microenvironment Promotes HER3-mediated Cell Survival in KRAS Wild-type and Mutant Colorectal Cancer

  2021cites this paper
• Liver Endothelium Promotes HER3-mediated Cell Survival in KRAS Wild-type and Mutant Colorectal Cancer Cells

  2021cites this paper
• Precision oncology in metastatic colorectal cancer — from biology to medicine

  2021cites this paper
• Not All Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations Predict Poor Survival in Patients With Unresectable Colorectal Liver Metastasis

  2021cites this paper
• The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non‐coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles

  2021cites this paper
• Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies

  2021cites this paper
• Targeting PI3K/Akt signal transduction for cancer therapy

  2021cites this paper
• Identification of AKT1/β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment.

  2021cites this paper
• Protein Arginine Methyltransferase 5 as a Therapeutic Target for KRAS Mutated Colorectal Cancer

  2020cites this paper
• Diverse Roles of Annexin A6 in Triple-Negative Breast Cancer Diagnosis, Prognosis and EGFR-Targeted Therapies

  2020cites this paper
• Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab.

  2020influential citation
• DHX33 promotes colon cancer development downstream of Wnt signaling.

  2020cites this paper
• Intra-Tumoral Genomic Heterogeneity in Rectal Cancer: Mutational Status Is Dependent on Preoperative Biopsy Depth and Location

  2020cites this paper
• KRAS and PIK3CA bi-mutations predict a poor prognosis in colorectal cancer patients: A single-site report

  2020cites this paper
• Phosphatidylinositol 3-kinase signalling is spatially organized at endosomal compartments by microtubule-associated protein 4

  2020cites this paper
• Fusobacterium nucleatum facilitates cetuximab resistance in colorectal cancer via the PI3K/AKT and JAK/STAT3 pathways

  2020cites this paper
• Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer

  2020cites this paper
• Histone methyltransferase WHSC1 inhibits colorectal cancer cell apoptosis via targeting anti-apoptotic BCL2

  2020cites this paper
• Molecular Targets for the Treatment of Metastatic Colorectal Cancer

  2020cites this paper
• MR cell size imaging with temporal diffusion spectroscopy.

  2020cites this paper
• Blocking histone methyltransferase SETDB1 inhibits tumorigenesis and enhances cetuximab sensitivity in colorectal cancer.

  2020cites this paper
• Mechanism of action of a T cell-dependent bispecific antibody as a breakthrough immunotherapy against refractory colorectal cancer with an oncogenic mutation

  2020cites this paper
• FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma

  2020cites this paper
• Endocannabinoids as Therapeutic Targets.

  2019cites this paper
• Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts

  2019cites this paper
• PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis

  2019influential citation
• In vivo magnetic resonance imaging of treatment-induced apoptosis

  2019cites this paper
• Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms

  2019cites this paper
• Anti-Apoptotic Effects of Docosahexaenoic Acid in IL-1β-Induced Human Chondrosarcoma Cell Death through Involvement of the MAPK Signaling Pathway

  2019cites this paper
• Single-Cell Analysis of Circulating Tumor Cells: Why Heterogeneity Matters

  2019cites this paper
• Oncogenes: new targets in cancer treatment

  2019cites this paper
• Associations of PIK3CA mutations with clinical features and prognosis in gastric cancer.

  2019cites this paper
• Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib

  2019cites this paper
• Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12

  2019cites this paper
• Long-term survival of an elderly female with metastatic colon cancer after treated with capecitabine monotherapy

  2019cites this paper
• PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target

  2019cites this paper
• F-box and leucine-rich repeat protein 5 promotes colon cancer progression by modulating PTEN/PI3K/AKT signaling pathway.

  2018cites this paper
• Role of Tyrosine Kinases in Gastrointestinal Malignancies

  2018cites this paper
• Sirtuin 6 inhibits colon cancer progression by modulating PTEN/AKT signaling.

  2018cites this paper
• Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth

  2018cites this paper
• Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal Cancer

  2018cites this paper
• Pharmacological Inhibition of Casein Kinase 2 Enhances the Effectiveness of PI3K Inhibition in Colon Cancer Cells

  2018cites this paper
• Curcumin suppresses gastric cancer biological activity by regulation of miRNA-21: an in vitro study.

  2018cites this paper
• EGFR and FGFR in Growth and Metastasis of Colorectal Cancer

  2018cites this paper
• Tumor Heterogeneity in Primary Colorectal Cancer and Corresponding Metastases. Does the Apple Fall Far From the Tree?

  2018cites this paper
• Functional Consequences and Clinical Significance of Tyrosine Kinase Inhibitors in Advanced Colorectal Cancer

  2018cites this paper
• Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer

  2018cites this paper
• Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study

  2018cites this paper
• An Insight in Biomarkers for Colorectal Cancer

  2018cites this paper
• Cetuximab promotes SN38 sensitivity via suppression of heat shock protein 27 in colorectal cancer cells with wild-type RAS.

  2017cites this paper
• Present and future of metastatic colorectal cancer treatment: A review of new candidate targets

  2017cites this paper
• Telomere length regulation through epidermal growth factor receptor signaling in cancer

  2017cites this paper
• Cudraflavone C Induces Tumor-Specific Apoptosis in Colorectal Cancer Cells through Inhibition of the Phosphoinositide 3-Kinase (PI3K)-AKT Pathway

  2017cites this paper
• Network based stratification of major cancers by integrating somatic mutation and gene expression data

  2017cites this paper
• The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation

  2017cites this paper
• Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers

  2017cites this paper
• lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling

  2017cites this paper
• Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.

  2017cites this paper
• Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance.

  2017cites this paper
• Histone hypoacetylation contributes to CXCL12 downregulation in colon cancer: impact on tumor growth and cell migration

  2017cites this paper
• In vitro and in vivo study of cannabinoids as modulators of Wnt/β-catenin pathway in human colorectal cancer

  2017cites this paper
• High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab

  2017cites this paper
• Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges.

  2017cites this paper
• From tumour heterogeneity to advances in precision treatment of colorectal cancer

  2017cites this paper
• Inhibition of Wnt/β-Catenin pathway and Histone acetyltransferase activity by Rimonabant: a therapeutic target for colon cancer

  2017cites this paper
• Current Tissue Molecular Markers in Colorectal Cancer: A Literature Review

  2017influential citation
• Role of PLCγ1 in the Resistance Mechanism to Anti-EGFR Therapy in Metastatic Colorectal Cancer

  2017cites this paper
• Molecular Testing in Colorectal Cancer

  2017cites this paper
• A Critical Review on the Effect of Docosahexaenoic Acid (DHA) on Cancer Cell Cycle Progression

  2017cites this paper
• Role of circulating free DNA in colorectal cancer

  2016cites this paper